Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

It promises the benefits of a 10,000-step walk in just 30 minutes. No gym membership required. Just a pair of shoes and a ...

Dementia in Asia-Pacific is expected to triple by the end of the decade. In Asia's fast ageing populations, including ...

New drugs show promise, and research finds value in vaccines, antivirals, exercise and probiotics.

One-third of people older than 85 in the United States are estimated to live with Alzheimer's disease today, according to the ...

Regina Barber and Rachel Carlson of Short Wave talk about endangered eagles in Japan, the lifestyles of deep-living ocean ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

In a major new finding almost a decade in the making, researchers at Harvard Medical School say they’ve found a key that may ...

This research offers hope. By finding brain diseases earlier, we might be able to slow them down or manage them better. If ...

SNAP participants showed a slower decline in cognitive function over 10 years, essentially maintaining up to three additional ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

A magnitude 8.7 earthquake struck off Russia's Far Eastern Kamchatka Peninsula on Wednesday, generating a tsunami of up to 13 feet, damaging buildings and prompting evacuation warnings in the area ...